Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme
This study has been withdrawn prior to recruitment.
( This study has been withdrawn because the drug would not meet trial criteria for efficacy )
Study NCT00083447   Information provided by Xenova Biomedix
First Received: May 24, 2004   Last Updated: January 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Glioblastoma Multiforme
Additional conditions recognized in this trial
Glioblastoma
More general conditions related to this trial
Astrocytoma
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Interventions listed in this trial
TransMID™
Sponsors listed in this trial
Xenova Biomedix


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services